Friday, 16 March 2007

Sartrezine


Scientists have recently explained the experience of spirituality, transcendence, and religiosity. The problem was identified to be 5-hydroxytryptamine re-uptake rates within the Substantia Nigra. The condition, initially thought to affect 48% of the population, is due to a mutation in the gene SLC6A4.

Pfizer have subsequently developed a drug treatment, and human trials of Sartrezine have begun.

Initial results have proven positive. People who reported feelings of interconnectedness with the universe and/or a faith in God, experienced a marked reduction in symptoms within 4 days of treatment. Placebo patients reported similar effects, but at a significantly lower rate.

Many patients who actively participated in organised religious ritual however, continued to display these behaviours, regardless of blood serum levels of Satrezine. A faith in God it has been proposed, has no clear correlation to religious behaviour. In some cases, a marked increase in these behaviours were noted, with a concomitant shift towards Conservative political bias.

Some serious side effects to Sartrezine have been reported. Relationship difficulties, emotional bluntness and irresponsible behaviour have been noted in 25% of patients.

The National Institute for Clinical Excellence is investigating its effectiveness for use in the NHS.

4 comments:

Unknown said...

;)

Anonymous said...

So, the ability to sense the very real interconnectivity of the universe as a seamless whole is in fact a genetic disorder? Astonishing. Perhaps this wonder-drug would be great as an ingredient for the Kool-Aid.

jamon said...

Yes Murph, a disorder.

Who'd have thought it.

thathe said...

a fantastic readRead Full Article see it hereGet the facts find thiswikipedia reference